TRIAL DETAIL

AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors

Drug:
Trial Name:
AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
NCT#:
Conditions:
Solid Tumors
Status:
Ongoing, but not recruiting
Phase:
2
Start Date 01/01/2009
Age of Trial (yrs) 13.5
Treatment Phase:
Gleevec-resistant
Drug Category:
IGF1R inhibitor + DR5 Inhibitor
Strategy:
Block related tumor signal paths
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
20070411
Sponsor:
Amgen
Patient Contact:
Amgen Call Center 866-572-6436
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Intravenous
Trial Notes:
Excludes patients who have received prior IGF-1R inhibitor therapy. Marked as "no GIST allowed' pending confirmation from Jennifer Ott at University of Chicago. Trial is about to enter phase 2. Verified that trial will accept GIST with Hedy Kindler.

Trial Links

Trial Results

 

Drug Information

Trial Sites

Name
Address
City
State
Zip
Country
2811 Wilshire Blvd
Santa Monica
CA
90403
USA
Indianapolis
IN
USA
Detroit
MI
USA
Barcelona
08036
Spain
1500 E. Duarte Road
Duarte
CA
91010
USA
Palo Alto
CA
94304
USA
660 S. Euclid Ave
St. Louis
MO
63110
USA
2220 Pierce Ave.
Nashville
TN
37232
USA
Los Angeles
CA
USA
Chicago
IL
USA
Harvey
IL
USA
Baltimore
MD
USA
Boston
MA
02115
USA
Chapel Hill
NC
USA
Durham
NC
USA
Philadelphia
PA
USA
Ogden
UT
USA
Valencia
46009
Spain